- Report
- February 2026
- 250 Pages
Global
From €3969EUR$4,490USD£3,439GBP
- Report
- December 2025
- 200 Pages
Global
From €2643EUR$2,990USD£2,290GBP
- Report
- February 2026
- 250 Pages
Global
From €3969EUR$4,490USD£3,439GBP
- Report
- April 2026
- 485 Pages
Global
From €5171EUR$5,850USD£4,480GBP
- Report
- April 2026
- 483 Pages
Global
From €5171EUR$5,850USD£4,480GBP
- Report
- April 2026
- 377 Pages
Global
From €5171EUR$5,850USD£4,480GBP
- Report
- January 2026
- 186 Pages
Global
From €3978EUR$4,500USD£3,447GBP
- Drug Pipelines
- June 2025
- 200 Pages
Global
From €2465EUR$2,789USD£2,136GBP
- Report
- November 2025
- 196 Pages
Global
From €4375EUR$4,950USD£3,791GBP
- Report
- June 2025
- 200 Pages
United States
From €2201EUR$2,490USD£1,907GBP
- Report
- August 2022
- 115 Pages
Global
From €3978EUR$4,500USD£3,447GBP
- Report
- June 2024
- 185 Pages
Global
From €3978EUR$4,500USD£3,447GBP
- Drug Pipelines
- April 2025
- 80 Pages
Global
From €2210EUR$2,500USD£1,915GBP
- Drug Pipelines
- April 2025
- 60 Pages
Global
From €1105EUR$1,250USD£957GBP
- Report
- August 2024
- 233 Pages
Global
From €7027EUR$7,950USD£6,089GBP
- Report
- January 2024
- 395 Pages
Global
From €6629EUR$7,500USD£5,744GBP
- Drug Pipelines
- August 2024
- 150 Pages
Global
From €2465EUR$2,789USD£2,136GBP
- Report
- May 2024
- 132 Pages
Global
From €3535EUR$3,999USD£3,063GBP
- Report
- May 2024
- 138 Pages
Global
From €3535EUR$3,999USD£3,063GBP
- Report
- May 2024
- 128 Pages
Global
From €3535EUR$3,999USD£3,063GBP

Epidiolex is a pharmaceutical drug used to treat certain types of epilepsy. It is the first FDA-approved drug derived from cannabidiol (CBD), a component of the cannabis plant. Epidiolex is used to treat two rare and severe forms of epilepsy, Lennox-Gastaut syndrome and Dravet syndrome, in patients two years of age and older. It is classified as a central nervous system (CNS) drug, which are drugs that act on the brain and spinal cord to treat neurological disorders.
Epidiolex is manufactured by GW Pharmaceuticals, a British biopharmaceutical company. It is distributed in the United States by Greenwich Biosciences, a subsidiary of GW Pharmaceuticals. Other companies in the CNS drug market include AbbVie, Allergan, Eli Lilly, Johnson & Johnson, Merck, Novartis, Pfizer, and Sanofi. Show Less Read more